ReviewSaudi journal of medicine & medical sciences
Non-alcoholic Wernicke-Korsakoff Syndrome: A Narrative Review.
Review in Saudi journal of medicine & medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic Wernicke-Korsakoff Syndrome (NA-WKS) is an under-recognised, thiamine-deficiency-mediated neurological disorder. While classically linked to chronic alcoholism, NA-WKS occurs in non-alcoholic patients. NA-WKS usually presents with episodes of anterograde amnesia accompanied by oculomotor signs, which occur more frequently than in alcoholic WKS. NA-WKS typically follows bariatric surgery, hyperemesis gravidarum, cancer cachexia, eating disorders, chronic kidney disease, or the use of certain oncologic or antidiabetic agents and chronic infectious diseases (e.g., immunodeficiency syndrome, tuberculosis, severe infections). Late diagnosis remains one of the leading factors for irreversible cognitive impairment. High-dose intravenous thiamine can reverse acute Wernicke encephalopathy when given early and prevent long-term damage. This review aims to provide clinicians with evidence based guidance regarding NA WKS to facilitate early recognition, timely treatment, and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.